4-(1,2,3-硫二唑-4-基)苄胺 | 175205-53-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(1,2,3-硫二唑-4-基)苄胺
• 中文别名: 4-(1,2,3-噻二唑-4-基)苄胺
• 英文名称: 4-(1,2,3-Thiadiazol-4-yl)benzamide
• 英文别名: 4-(thiadiazol-4-yl)benzamide
• CAS: 175205-53-5
• 化学式: C₉H₇N₃OS
• mdl: MFCD00173809
• 分子量: 205.24
• InChiKey: PAVNUEROKSNSDS-UHFFFAOYSA-N

物化性质

• 沸点：
  423.5±47.0 °C(Predicted)
• 密度：
  1.374±0.06 g/cm3(Predicted)
• 溶解度：
  8.1 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  97.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 安全说明：
  S24/25

文献信息

• Pyrazole compounds and their use as antidiabetes agents
  申请人：Takagi Masaki

  公开号：US20070032529A1

  公开（公告）日：2007-02-08

  The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R 1 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group, R 2 represents a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or an azido group, R 3 represents a halogen atom, a hydroxyl group, a C 1-6 alkyl group, a halo C 1-6 alkyl group, a C 1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C 1-6 alkylsulfonylamino group, R 4 and R 5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C 1-6 alkyl group, a C 3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C 7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.

  本发明提供了一种具有肝糖原磷酸化酶抑制活性的吡唑化合物，用作糖尿病的治疗或预防剂，所述吡唑化合物由以下通用式（I）表示：其中环Q代表芳基或杂芳基，R1代表氢原子、卤原子、C1-6烷基或C1-6烷氧基，R2代表卤原子、C1-6烷基、C1-6烷氧基或偶氮基，R3代表卤原子、羟基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、偶氮基、氨基、酰胺基或C1-6烷基磺酰胺基，R4和R5彼此相同或不同，代表氢原子、取代或未取代的C1-6烷基、取代或未取代的C3-8环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14芳基烷基、杂芳基等，或其药理学上可接受的盐。
• Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them
  申请人：Rossi Cristina

  公开号：US20080207694A1

  公开（公告）日：2008-08-28

  Compounds of structure (I) having histone deacetylase (HDAC) inhibitor activity are described. The compounds are chemically characterised by the presence of hydroxamic acid, with zinc as chelator, and an aromatic nucleus connected by a linker in which either a bicyclic aromatic system or a piperidino ring are present.

  结构（I）的化合物具有组蛋白去乙酰化酶（HDAC）抑制剂活性。这些化合物在化学上特征为存在羟肟酸，锌作为螯合剂，并且通过连接剂连接的芳香核与一个双环芳香系统或哌啶环存在。
• PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME
  申请人：Japan Tobacco, Inc.

  公开号：EP1884513A1

  公开（公告）日：2008-02-06

  The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R1 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, R2 represents a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or an azido group, R3 represents a halogen atom, a hydroxyl group, a C1-6 alkyl group, a halo C1-6 alkyl group, a C1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C1-6 alkylsulfonylamino group, R4 and R5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C1-6 alkyl group, a C3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.

  本发明提供了一种具有肝糖原磷酸化酶抑制活性并可用作糖尿病治疗或预防剂的吡唑化合物，该吡唑化合物由以下通式(I)表示： 其中环 Q 代表芳基或杂芳基，R1 代表氢原子、卤素原子、C1-6 烷基或 C1-6 烷氧基，R2 代表卤素原子、C1-6 烷基、C1-6 烷氧基或叠氮基，R3 代表卤素原子、羟基、C1-6 烷基、卤代 C1-6 烷基、C1-6 烷氧基、叠氮基、氨基、酰氨基或酰胺基、R4 和 R5 彼此相同或不同，代表氢原子、取代或未取代的 C1-6 烷基、C3-8 环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14 芳基、杂芳基或类似基团，或其药理学上可接受的盐。
• HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM
  申请人：Menarini International Operations Luxembourg S.A.

  公开号：EP1868997A1

  公开（公告）日：2007-12-26
• 1,3-DISUBSTITUIERTE 4-METHYL-1 H-PYRROL-2-CARBONSÄUREAMIDE UND IHRE VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN
  申请人：Grünenthal GmbH

  公开号：EP2035375B1

  公开（公告）日：2011-01-19